デフォルト表紙
市場調査レポート
商品コード
1500781

疼痛緩和パッチ市場:世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年

Pain Relief Patches Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033


出版日
ページ情報
英文 250 Pages
納期
2~5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
疼痛緩和パッチ市場:世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年
出版日: 2024年06月14日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、疼痛緩和パッチの世界市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題を含む重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主な洞察:疼痛緩和パッチ市場

  • 市場規模(2024年):12億米ドル
  • 予測市場価値(2033年):19億米ドル
  • 世界市場成長率(CAGR 2024年~2033年):5.2%

疼痛緩和パッチ市場- 調査範囲:

疼痛緩和パッチは、様々な種類の疼痛の治療において重要な役割を果たし、有効医薬品成分(API)の経皮投与による局所的な緩和を提供します。これらのパッチは、経口薬や侵襲的な治療に代わるものとして、臨床現場、在宅ケア環境、スポーツ医療などで広く使用されています。同市場は、筋骨格系の疼痛、関節炎、術後の疼痛管理など、多様な疼痛症状に対応しています。

市場促進要因:

世界の疼痛緩和パッチ市場は、関節炎や腰痛などの慢性疼痛症状の有病率の増加など、いくつかの重要な要因によって牽引されています。非侵襲的な疼痛管理ソリューションへのシフトと局所的な薬物送達方法への嗜好が市場拡大に大きく寄与しています。粘着性の向上や薬物放出の延長といったパッチデザインの技術的進歩は、患者の快適性と治療効果を高め、市場の成長をさらに刺激しています。

市場抑制要因:

有望な成長見通しにもかかわらず、疼痛緩和パッチ市場は、規制当局の承認、特にパッチの医療機器または医薬品としての分類に関する課題に直面しています。また、地域によって償還政策が異なることや、特定のパッチ製剤に関連する皮膚刺激やアレルギー反応に関する懸念も市場浸透の妨げとなっています。

市場機会:

疼痛緩和パッチ市場は、パッチ技術の進歩と、非オピオイド系疼痛管理オプションに対する消費者の意識の高まりによって、大きな成長機会をもたらしています。革新的な製剤を開発し市場参入を拡大するための製薬企業とパッチメーカーの戦略的提携は、新たな機会を生かすものと期待されます。さらに、遠隔医療やeコマースプラットフォームによる疼痛緩和パッチの流通が拡大していることで、多様な患者層がこれらの製品にアクセスできるようになっています。

本レポートで扱う主な質問

  • 疼痛緩和パッチ市場の世界的成長を促進する主な要因は何か?
  • 疼痛緩和パッチの採用を促進する痛みの状態や患者層は何か?
  • 技術進歩は疼痛緩和パッチ市場の競合情勢をどのように変えているか?
  • 疼痛緩和パッチ市場に貢献している主要企業はどこか、また市場の関連性を維持するためにどのような戦略を採用しているか?
  • 世界の疼痛緩和パッチ市場の新たな動向と将来展望は?

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • イノベーション/開発動向

第4章 重要成功要因

  • 主要プレーヤー別の主要プロモーション戦略
  • 製品の採用/使用状況分析
  • 技術評価
  • 規制シナリオ
  • バリューチェーン分析
  • ポーターの分析
  • PESTEL分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 製品別
    • 適応症別
    • 流通チャネル別
    • 地域別
  • 2024年の市場シナリオ

第7章 世界市場の価格分析

  • 地域別価格分析(製品タイプ別)
  • 世界平均価格分析ベンチマーク
  • 価格設定の前提

第8章 世界市場の需要(金額)分析

  • 過去の市場規模(金額)分析、2019~2023年
  • 現在および将来の市場規模(金額)分析と予測、2024~2033年
    • 前年比成長分析
    • 絶対的収益機会分析

第9章 世界市場分析、製品別

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019年~2023年
  • 現在および将来の市場規模(金額)の分析と予測、製品別、2024~2033年
    • 非ステロイド性抗炎症薬パッチ
    • ケトロプロフェンパッチ
    • ジクロフェナクパッチ
    • フルルビプロフェンパッチ
    • ピロキシカムパッチ
    • オピオイドパッチ
    • フェンタニルパッチ
    • ブプレノルフィン
    • 局所麻酔パッチ
    • ニトログリセリンパッチ
    • カプサイシンパッチ
    • リドカインパッチ
  • 製品別市場の魅力分析

第10章 世界市場分析、指標別

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019年~2023年
  • 現在および将来の市場規模(金額)の分析と予測、適応症別、2024~2033年
    • 月経痛
    • 整形外科的疼痛
    • 神経障害性疼痛
    • 術後の痛み
    • 心臓血管の痛み
    • その他
  • 症状別の市場の魅力分析

第11章 世界市場分析、流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)分析、2019年~2023年
  • 現在および将来の市場規模(金額)の分析と予測、流通チャネル別、2024~2033年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別市場の魅力分析

第12章 世界市場分析、地域別

  • イントロダクション
  • 過去の市場規模(金額)分析、地域別、2019年~2023年
  • 現在および将来の市場規模(金額)の分析と予測、地域別、2024~2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ(中東・アフリカ)
  • 地域別市場の魅力分析

第13章 北米の市場分析

第14章 ラテンアメリカの市場分析

第15章 欧州の市場分析

第16章 南部の市場分析

  • イントロダクション
  • 過去の市場規模(金額)分析、分類別、2019年~2023年
  • 現在および将来の市場規模(金額)の分析と予測、分類別、2024~2033年
    • 国別
      • インド
      • タイ
      • インドネシア
      • マレーシア
      • その他の南アジア
    • 製品別
    • 適応症別
    • 流通チャネル別
  • 市場の魅力分析
  • 市場動向
  • 主要な市場参入企業-強度マッピング
  • 促進要因と制約- 影響分析
  • 国レベルの分析と予測

第17章 東部の市場分析

  • イントロダクション
  • 過去の市場規模(金額)分析、分類別、2019年~2023年
  • 現在および将来の市場規模(金額)の分析と予測、分類別、2024~2033年
    • 国別
      • 中国
      • 日本
      • 韓国
    • 製品別
    • 適応症別
    • 流通チャネル別
  • 市場の魅力分析
  • 市場動向
  • 主要な市場参入企業-強度マッピング
  • 促進要因と制約-影響分析
  • 国レベルの分析と予測

第18章 オセアニア市場分析

第19章 中東・アフリカ(MEA)市場分析

第20章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • テクノロジーの足跡

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Viatris, Inc.(Mylan)
    • Obalon Therapeutics, Inc.
    • Johnson &Johnson Services, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Hisamitsu Pharmaceutical Co., Inc.
    • GlaxoSmithKline Plc.
    • Novartis AG
    • Nichiban Co., Ltd.
    • Teikoku Seiyaku Co, Ltd.
    • Mentholatum Company.
    • Purdue Pharma LP
    • West-Ward Pharmaceuticals Corporation
    • Pfizer, Inc
    • Allergan Plc(Actavis)
    • Endo International plc,
    • Mylan NV

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP33349

Persistence Market Research has recently released a comprehensive report on the worldwide market for pain relief patches. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights: Pain Relief Patches Market

  • Market Size (2024E): USD 1.2 Billion
  • Projected Market Value (2033F): USD 1.9 Billion
  • Global Market Growth Rate (CAGR 2024 to 2033): 5.2%

Pain Relief Patches Market - Report Scope:

Pain relief patches play a crucial role in the treatment of various types of pain, offering localized relief through transdermal delivery of active pharmaceutical ingredients (APIs). These patches are used widely in clinical settings, homecare environments, and sports medicine, providing alternatives to oral medications and invasive treatments. The market caters to a diverse range of pain conditions, including musculoskeletal pain, arthritis, and post-operative pain management.

Market Growth Drivers:

The global pain relief patches market is driven by several key factors, including increasing prevalence of chronic pain conditions such as arthritis and lower back pain. The shift towards non-invasive pain management solutions and the preference for localized drug delivery methods contribute significantly to market expansion. Technological advancements in patch design, such as improved adhesion and prolonged drug release capabilities, enhance patient comfort and treatment efficacy, further stimulating market growth.

Market Restraints:

Despite promising growth prospects, the pain relief patches market faces challenges related to regulatory approvals, particularly concerning the classification of patches as medical devices or pharmaceutical products. Variations in reimbursement policies across different regions and concerns regarding skin irritation and allergic reactions associated with certain patch formulations also hinder market penetration.

Market Opportunities:

The pain relief patches market presents significant growth opportunities driven by advancements in patch technology and increasing consumer awareness about non-opioid pain management options. Strategic collaborations between pharmaceutical companies and patch manufacturers to develop innovative formulations and expand market reach are expected to capitalize on emerging opportunities. Moreover, the growing adoption of telemedicine and e-commerce platforms for the distribution of pain relief patches broadens access to these products across diverse patient demographics.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the pain relief patches market globally?
  • Which pain conditions and patient demographics are driving adoption of pain relief patches?
  • How are technological advancements reshaping the competitive landscape of the pain relief patches market?
  • Who are the key players contributing to the pain relief patches market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global pain relief patches market?

Competitive Intelligence and Business Strategy:

Leading players in the global pain relief patches market, including [Company A], [Company B], and [Company C], focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced patch formulations, enhance drug delivery capabilities, and improve patient compliance. Collaborations with healthcare providers and retail distributors facilitate market expansion, while investments in clinical research and regulatory compliance ensure product safety and efficacy.

Key Companies Profiled:

  • Viatris, Inc. (Mylan)
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Hisamitsu Pharmaceutical Co., Inc.
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Nichiban Co., Ltd.
  • Teikoku Seiyaku Co, Ltd.
  • Mentholatum Company
  • Purdue Pharma L.P.
  • West-Ward Pharmaceuticals Corporation
  • Pfizer, Inc
  • Allergan PLC (Actavis)
  • Endo International PLC
  • Mylan N.V.
  • Corium, Inc.
  • Agile Therapeutics Inc.

Pain Relief Patches Industry Research Segmentation

By Product Type:

  • Non-steroidal Anti-inflammatory Drug Patches
  • Opioid Patches
  • Local Anesthetic Patches

By Indication:

  • Menstrual Cramps
  • Orthopedic Pain
  • Neuropathic Pain
  • Post-operative Pain
  • Cardiovascular Pain
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Key Promotional Strategies, By Key Player
  • 4.2. Product Adoption/Usage Analysis
  • 4.3. Technology Assessment
  • 4.4. Regulatory Scenario
  • 4.5. Value Chain Analysis
  • 4.6. Porter's Analysis
  • 4.7. PESTEL analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Market Outlook
    • 5.1.3. Per Capita Healthcare Spending Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Top Companies Historical Growth
    • 5.2.2. Product Adoption Rate and Demand
    • 5.2.3. New Product Launches
    • 5.2.4. Increase in Demand for Non-invasive Pain Management Treatment
    • 5.2.5. Changing Regulatory Dynamics
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Product
    • 6.1.2. By Indication
    • 6.1.3. By Distribution Channel
    • 6.1.4. By Region
  • 6.2. 2024 Market Scenario

7. Global Market Pricing Analysis

  • 7.1. Regional Pricing Analysis, By Product Type
  • 7.2. Global Average Pricing Analysis Benchmark
  • 7.3. Pricing Assumptions

8. Global Market Value US$ Mn Analysis 2019-2023 and Forecast, 2024-2033

  • 8.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 8.2. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
    • 8.2.1. Y-o-Y Growth Analysis
    • 8.2.2. Absolute $ Opportunity Analysis

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Product

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
    • 9.3.1. Non-Steroidal Anti- Inflammatory Drug Patches
    • 9.3.2. Ketroprofen Patches
    • 9.3.3. Diclofenac Patches
    • 9.3.4. Flurbiprofen Patches
    • 9.3.5. Piroxicam Patches
    • 9.3.6. Opioid Patches
    • 9.3.7. Fentanyl Patches
    • 9.3.8. Buprenorphine
    • 9.3.9. Local Anaesthetic Patches
    • 9.3.10. Nitro-glycerin Patches
    • 9.3.11. Capsaicin Patches
    • 9.3.12. Lidocaine Patches
  • 9.4. Market Attractiveness Analysis By Product

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2033
    • 10.3.1. Menstrual Cramps
    • 10.3.2. Orthopedic Pain
    • 10.3.3. Neuropathic Pain
    • 10.3.4. Post-Operative Pain
    • 10.3.5. Cardiovascular Pain
    • 10.3.6. Others
  • 10.4. Market Attractiveness Analysis By Indication

11. Global Market analysis 2019-2023 and forecast 2024-2033, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis by Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Product
    • 13.3.3. By Indication
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Indication
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Indication
        • 13.8.1.2.3. By Distribution Channel
    • 13.8.2. Canada Market
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Indication
        • 13.8.2.2.3. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Rest of Latin America
    • 14.3.2. By Product
    • 14.3.3. By Indication
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Indication
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Indication
        • 14.8.1.2.3. By Distribution Channel
    • 14.8.2. Argentina Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Indication
        • 14.8.2.2.3. By Distribution Channel
    • 14.8.3. Mexico Market
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Indication
        • 14.8.3.2.3. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Russia
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Product
    • 15.3.3. By Indication
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Indication
    • 15.4.4. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Indication
        • 15.8.1.2.3. By Distribution Channel
    • 15.8.2. France Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Indication
        • 15.8.2.2.3. By Distribution Channel
    • 15.8.3. Italy Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Indication
        • 15.8.3.2.3. By Distribution Channel
    • 15.8.4. Spain Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Indication
        • 15.8.4.2.3. By Distribution Channel
    • 15.8.5. U.K. Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By Indication
        • 15.8.5.2.3. By Distribution Channel
    • 15.8.6. Benelux Union Market
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Product
        • 15.8.6.2.2. By Indication
        • 15.8.6.2.3. By Distribution Channel
    • 15.8.7. Russia Market
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Product
        • 15.8.7.2.2. By Indication
        • 15.8.7.2.3. By Distribution Channel

16. South Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Product
    • 16.3.3. By Indication
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By Indication
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Indication
        • 16.8.1.2.3. By Distribution Channel
    • 16.8.2. Indonesia Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Indication
        • 16.8.2.2.3. By Distribution Channel
    • 16.8.3. Thailand Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Indication
        • 16.8.3.2.3. By Distribution Channel
    • 16.8.4. Malaysia Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Product
        • 16.8.4.2.2. By Indication
        • 16.8.4.2.3. By Distribution Channel

17. East Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Product
    • 17.3.3. By Indication
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Indication
    • 17.4.4. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Market
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Product
        • 17.8.1.2.2. By Indication
        • 17.8.1.2.3. By Distribution Channel
    • 17.8.2. Japan Market
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Product
        • 17.8.2.2.2. By Indication
        • 17.8.2.2.3. By Distribution Channel
    • 17.8.3. South Korea Market
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Product
        • 17.8.3.2.2. By Indication
        • 17.8.3.2.3. By Distribution Channel

18. Oceania Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Product
    • 18.3.3. By Indication
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Product
    • 18.4.3. By Indication
    • 18.4.4. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Product
        • 18.8.1.2.2. By Indication
        • 18.8.1.2.3. By Distribution Channel
    • 18.8.2. New Zealand Market
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Product
        • 18.8.2.2.2. By Indication
        • 18.8.2.2.3. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Bn)Analysis and Forecast By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkiye
      • 19.3.1.3. North Africa
      • 19.3.1.4. South Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Product
    • 19.3.3. By Indication
    • 19.3.4. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Product
    • 19.4.3. By Indication
    • 19.4.4. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Product
        • 19.8.1.2.2. By Indication
        • 19.8.1.2.3. By Distribution Channel
    • 19.8.2. Turkiye Market
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Product
        • 19.8.2.2.2. By Indication
        • 19.8.2.2.3. By Distribution Channel
    • 19.8.3. South Africa Market
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Product
        • 19.8.3.2.2. By Indication
        • 19.8.3.2.3. By Distribution Channel
    • 19.8.4. North Africa Market
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Product
        • 19.8.4.2.2. By Indication
        • 19.8.4.2.3. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Technology Footprint

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Viatris, Inc. (Mylan)
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Key Financials
      • 21.3.1.4. SWOT Analysis
      • 21.3.1.5. Sales Footprint
      • 21.3.1.6. Key Developments
      • 21.3.1.7. Strategy Overview
    • 21.3.2. Obalon Therapeutics, Inc.
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Key Financials
      • 21.3.2.4. SWOT Analysis
      • 21.3.2.5. Sales Footprint
      • 21.3.2.6. Key Developments
      • 21.3.2.7. Strategy Overview
    • 21.3.3. Johnson & Johnson Services, Inc.
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Key Financials
      • 21.3.3.4. SWOT Analysis
      • 21.3.3.5. Sales Footprint
      • 21.3.3.6. Key Developments
      • 21.3.3.7. Strategy Overview
    • 21.3.4. Teva Pharmaceutical Industries Ltd.
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Key Financials
      • 21.3.4.4. SWOT Analysis
      • 21.3.4.5. Sales Footprint
      • 21.3.4.6. Key Developments
      • 21.3.4.7. Strategy Overview
    • 21.3.5. Sanofi S.A.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Key Financials
      • 21.3.5.4. SWOT Analysis
      • 21.3.5.5. Sales Footprint
      • 21.3.5.6. Key Developments
      • 21.3.5.7. Strategy Overview
    • 21.3.6. Hisamitsu Pharmaceutical Co., Inc.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Key Financials
      • 21.3.6.4. SWOT Analysis
      • 21.3.6.5. Sales Footprint
      • 21.3.6.6. Key Developments
      • 21.3.6.7. Strategy Overview
    • 21.3.7. GlaxoSmithKline Plc.
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Key Financials
      • 21.3.7.4. SWOT Analysis
      • 21.3.7.5. Sales Footprint
      • 21.3.7.6. Key Developments
      • 21.3.7.7. Strategy Overview
    • 21.3.8. Novartis AG
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Key Financials
      • 21.3.8.4. SWOT Analysis
      • 21.3.8.5. Sales Footprint
      • 21.3.8.6. Key Developments
      • 21.3.8.7. Strategy Overview
    • 21.3.9. Nichiban Co., Ltd.
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Key Financials
      • 21.3.9.4. SWOT Analysis
      • 21.3.9.5. Sales Footprint
      • 21.3.9.6. Key Developments
      • 21.3.9.7. Strategy Overview
    • 21.3.10. Teikoku Seiyaku Co, Ltd.
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Key Financials
      • 21.3.10.4. SWOT Analysis
      • 21.3.10.5. Sales Footprint
      • 21.3.10.6. Key Developments
      • 21.3.10.7. Strategy Overview
    • 21.3.11. Mentholatum Company.
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Key Financials
      • 21.3.11.4. SWOT Analysis
      • 21.3.11.5. Sales Footprint
      • 21.3.11.6. Key Developments
      • 21.3.11.7. Strategy Overview
    • 21.3.12. Purdue Pharma L.P.
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Key Financials
      • 21.3.12.4. SWOT Analysis
      • 21.3.12.5. Sales Footprint
      • 21.3.12.6. Key Developments
      • 21.3.12.7. Strategy Overview
    • 21.3.13. West-Ward Pharmaceuticals Corporation
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Key Financials
      • 21.3.13.4. SWOT Analysis
      • 21.3.13.5. Sales Footprint
      • 21.3.13.6. Key Developments
      • 21.3.13.7. Strategy Overview
    • 21.3.14. Pfizer, Inc
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Key Financials
      • 21.3.14.4. SWOT Analysis
      • 21.3.14.5. Sales Footprint
      • 21.3.14.6. Key Developments
      • 21.3.14.7. Strategy Overview
    • 21.3.15. Allergan Plc (Actavis)
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Key Financials
      • 21.3.15.4. SWOT Analysis
      • 21.3.15.5. Sales Footprint
      • 21.3.15.6. Key Developments
      • 21.3.15.7. Strategy Overview
    • 21.3.16. Endo International plc,
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Key Financials
      • 21.3.16.4. SWOT Analysis
      • 21.3.16.5. Sales Footprint
      • 21.3.16.6. Key Developments
      • 21.3.16.7. Strategy Overview
    • 21.3.17. Mylan N.V.
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Key Financials
      • 21.3.17.4. SWOT Analysis
      • 21.3.17.5. Sales Footprint
      • 21.3.17.6. Key Developments
      • 21.3.17.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology